Introduction {#s01}
============

Stomach cancer and esophageal cancer are huge threats to the health of Chinese people. According to International Agency for Research on Cancer (IARC), in 2012, 45% of global stomach cancer cases and 47% of global deaths occurred in China, the percentages for esophageal cancer were 50% and 50%, respectively ([@b1]). Such proportions were astonishingly high given that Chinese population was only one fifth of that of the world. Both cancers were among the most diagnosed cancers in China ([@b2]). It is estimated that 427,100 new stomach cancer cases and 301,200 deaths, and 276,900 new esophageal cancer cases and 206,500 deaths occurred in 2013 nationwide ([@b3]).

Compared with the abundant evidence on the epidemiological burden of stomach and esophageal cancer, only a few researches had been done concerning the economic burden of them at patient level in China ([@b4]-[@b6]). Moreover, these studies were carried out in either one area (county, province) ([@b5],[@b6]) or only urban areas ([@b4]). To date, in-depth studies on the cost of illness of stomach or esophageal cancer at patient level have been conducted mainly in developed countries ([@b7]-[@b12]). In the patients who survived beyond 1 year in Ontario, esophageal cancer was the costliest cancer while stomach cancer was the fifth costliest ([@b9]). Australian and British researchers unveiled that surgery and stage I were associated with higher hospitalization costs of esophageal cancer ([@b7],[@b8]), whereas a Korean study showed that advanced stages were associated with higher total costs ([@b10]). Furthermore, age was found to be positively associated with the hospitalization cost of stomach cancer by Japanese researchers ([@b11]).

In 2009, medical expenses due to stomach cancer treatment accounted for 10% of that of all cancers in Japan. A downward trend had been noticed nevertheless and was projected to continue in the near future ([@b13]). The payments of cancer inpatients in China, unlike Japan, had increased by 84.1% from 2011 to 2015, reaching a total of 28.4 billion US dollars. Of which, stomach and esophageal cancer accounted for approximately 2.0 and 1.2 billion respectively ([@b14]). Therefore, it is of vital importance to further investigate this tremendous financial burden of stomach and esophageal cancer in this country.

China was among the countries with the largest gains of Healthcare Quality and Access Index during 1990−2015 ([@b15]), thanks to the rapid economic development and health care reform ([@b16]). In 2009, Central Government of China launched a \$125 billion medical reform, aiming at achieving comprehensive universal health coverage by 2020 ([@b17]). To better understand the financial burden of Chinese patients with stomach and esophageal cancer, provide information for the amendment of the policy on cancer prevention and control, direct the medical insurance to a more efficient way, and consequently support the implementation of medical reform and enhance the quality of health service for the Chinese population, herein we provided an in-depth description of the annual cost of illness (ACI) of stomach cancer and esophageal cancer patients in China, using the data collected in seven cities/counties, where we carried out a randomized controlled trial (RCT) to evaluate the efficacy of screening for upper gastrointestinal cancer ([@b18]). Comparisons of the ACI were made as well, especially between urban and rural areas.

Materials and methods {#s02}
=====================

Data sources and collection {#s02.01}
---------------------------

Seven cities/counties, which are Harbin, Changsha, Linzhou, Cixian, Wuwei, Sheyang and Luoshan, were selected as study sites, covering both urban and rural areas in China with a vast geographical span as shown in *[Figure 1](#Figure1){ref-type="fig"}*. A detailed description of the selecting criteria of the study sites can be found in our previous article ([@b18]). The hospitals selected to participate in this study were either the largest or the only cancer hospital or general hospital in each city/county, being in charge of the medical service for the majority of the local residents. Altogether seven hospitals were selected, each in one of the seven study sites.

![Geographic distribution of seven study sites.](cjcr-30-4-439-1){#Figure1}

To obtain the cost per hospitalization (CPH), data of all patients discharged between 1st September 2015 and 31st August 2016 were extracted from the electronic medical record of the seven hospitals, with the primary discharge diagnosis being stomach cancer or esophageal cancer. Patients with both cancers were excluded. Besides demographic information, extracted data included the medical record number, ID number, date of admission, date of discharge, length of stay (LOS), clinical stage, pathologic type, primary treatment, total hospitalization cost and itemized hospitalization cost of each case. If any information happened to be missing or illogical, staff in the study sites would check manually in the paper medical record. Modification or deletion would be made according to the feedback.

To obtain the annual number of hospitalization, annual direct non-medical cost and annual indirect cost, we sampled the former patients of the seven hospitals discharged before 1st September 2015 diagnosed as stomach cancer or esophageal cancer. Patients with both cancers were excluded. We chose approximately 150 patients for each cancer in each area. Balance of sex and clinical stage were considered in the selection to ensure that the numbers of stage I to IV patients were not less than 30 in each area. Patients were selected backwardly based on the discharge date in the electronic medical record until the expected sample size was reached. Besides demographic information, we also collected ID number, discharge diagnosis, LOS, clinical stage, pathologic type, primary treatment, the number of hospitalization in the past year, direct non-medical cost (nutraceutical fee and commission to caregivers) and indirect cost (productivity loss of the patients and their family members) in the past year.

Statistical analysis {#s02.02}
--------------------

All treatments were classified into five modalities: surgery, radiotherapy, chemotherapy, concurrent chemoradiotherapy and palliative care. Pathologic types were classified into adenocarcinoma and other for stomach cancer, squamous cell carcinoma, adenocarcinoma and other for esophageal cancer, according to the distribution of all pathologic types of each cancer in Chinese population ([@b19],[@b20]). Patients were also categorized as elderly group (≥60 years old) and non-elderly group (\<60 years old). The hospitalization cost was itemized into eight parts: western medicine fee, diagnosis fee, material fee, surgery fee, non-surgical treatment fee, traditional Chinese medicine fee, ward fee and others. The proportion of each part in the total CPH was calculated.

Annual direct medical cost was calculated by multiplying the CPH extracted from the electronic medical record by the number of hospitalization of the sampled patients. ACI was calculated by adding the average values of annual direct medical cost, direct non-medical cost and indirect cost together. All costs were converted to 2016 US dollars (1 USD=6.6423 RMB).

After logarithm transition, two-sample Student's *t*-test was used for binary classification variables, and ANOVA test was used for other multiple categorical variables to compare the difference of CPH. All statistical tests were two-sided. P\<0.05 was considered statistically significant. All analyses were carried out using STATA (Version 14.2; StataCorp LLC, TX, USA).

Results {#s03}
=======

Distribution of patient-level characteristics {#s03.01}
---------------------------------------------

As shown in *[Table 1](#Table1){ref-type="table"}*, altogether 19,986 cases (13,528 with stomach cancer and 6,458 with esophageal cancer) were included in the analysis of CPH, with a mean age of 58.5 and 63.0 years for stomach and esophageal cancer patients respectively. Male patients were the majority by far. In all seven study sites, stage III and stage II were the most reported for stomach cancer and esophageal cancer respectively. The most prevalent pathologic type was adenocarcinoma (87.81%) for stomach cancer and squamous cell carcinoma (88.81%) for esophageal cancer. Chemotherapy was the most adopted treatment for both cancers. The mean LOS was 9.3 d for stomach cancer and 16.9 d for esophageal cancer while the median LOS was 7 d and 10 d, respectively.

###### 

Demographic and clinical characteristics of stomach and esophageal cancer patients by area

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                                n (%)                                                                              
  ------------------------------------------------------------------------ --------------- --------------- --------------- -- --------------- --------------- ---------------
  Sex                                                                                                                                                         

  　Male                                                                   9,666 (71.45)   5,745 (68.04)   3,921 (77.11)      5,239 (81.12)   2,997 (94.30)   2,242 (68.35)

  　Female                                                                 3,862 (28.55)   2,698 (31.96)   1,164 (22.89)      1,219 (18.88)   181 (5.70)      1,038 (31.65)

  Age (year)                                                                                                                                                  

  　 $\large\begin{document}$\, \overline{{x}}{{±}}{{s}}$\end{document}$   58.5±10.4       56.8±10.5       61.3±9.6           63.0±8.8        59.9±8.5        66.0±8.1

  　Median (P25−P75)                                                       60 (52--65)     58 (50--64)     62 (55--68)        63 (57--69)     60 (53--65)     66 (61--71)

  Age                                                                                                                                                         

  　Non-elderly                                                            7,393 (54.65)   5,132 (60.78)   2,261 (44.46)      2,462 (38.12)   1,689 (53.15)   773 (23.57)

  　Elderly                                                                6,135 (45.35)   3,311 (39.22)   2,824 (55.54)      3,996 (61.88)   1,489 (46.85)   2,507 (76.43)

  Clinical stage\*                                                                                                                                            

  　I                                                                      835 (11.50)     395 (12.24)     440 (10.90)        341 (10.54)     74 (8.84)       267 (11.13)

  　II                                                                     1,414 (19.47)   286 (8.87)      1,128 (27.94)      1,213 (37.50)   171 (20.43)     1,042 (43.45)

  　III                                                                    3,102 (42.71)   1,552 (48.11)   1,550 (38.39)      749 (23.15)     306 (36.56)     443 (18.47)

  　IV                                                                     1,912 (26.33)   993 (30.78)     919 (22.76)        932 (28.81)     286 (34.17)     646 (26.94)

  Pathologic type\*\*                                                                                                                                         

  　Adenocarcinoma                                                         7,719 (87.81)   3,422 (84.81)   4,297 (90.35)      151 (3.36)      92 (5.82)       59 (2.02)

  　Squamous cell\                                                         −               −               −                  3,992 (88.81)   1,398 (88.48)   2,594 (88.99)
  　carcinoma                                                                                                                                                 

  　Other                                                                  1,072 (12.19)   613 (15.19)     459 (9.65)         352 (7.83)      90 (5.70)       262 (8.99)

  Treatment                                                                                                                                                   

  　Surgery                                                                2,341 (17.30)   1,517 (17.97)   824 (16.20)        885 (13.70)     292 (9.19)      593 (18.08)

  　Radiotherapy                                                           560 (4.14)      20 (0.24)       540 (10.62)        1,273 (19.71)   212 (6.67)      1,061 (32.35)

  　Chemotherapy                                                           6,706 (49.57)   4,462 (52.85)   2,244 (44.13)      2,103 (32.56)   1,439 (45.28)   664 (20.24)

  　Concurrent\                                                            197 (1.46)      12 (0.14)       185 (3.64)         470 (7.28)      153 (4.81)      317 (9.66)
  　chemoradiotherapy                                                                                                                                         

  　Palliative care                                                        3,724 (27.53)   2,432 (28.80)   1,292 (25.41)      1,727 (26.74)   1,082 (34.05)   645 (19.66)

  LOS (d)                                                                                                                                                     

  　 $\large\begin{document}$\, \overline{{x}}{{±}}{{s}}$\end{document}$   9.3±6.9         8.9±6.2         9.9±7.9            16.9±16.1       15.0±16.0       18.7±16.0

  　Median (P25−P75)                                                       7 (5--12)       7 (5--12)       7 (5--12)          10 (6--21)      9 (6--16)       12 (7--25)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Patients were younger in urban areas than in rural areas for both cancers. Stage II was the most reported in rural esophageal cancer patients while stage III was the most reported in other subgroups. Mean LOS were longer in rural areas than in urban areas for both cancers. Chemotherapy was the most adopted treatment for stomach cancer patients in both areas as well as esophageal cancer patients in urban areas, while in rural areas radiotherapy was the most adopted for esophageal cancer patients. Distribution of demographic and clinical characteristics of former patients included in the analysis of numbers of hospitalization, annual direct non-medical cost and annual indirect cost could be found in *[Supplementary Table S1](#TableS1){ref-type="table"}*.

###### 

Demographic and clinical characteristics of sampled former stomach and esophageal cancer patients by area

  ----------------------------------------------------------------------------------------------------------------
  Variables             n (%)                                                                        
  --------------------- --------------- ------------- ------------- -- --------------- ------------- -------------
  Sex                                                                                                

  　Male                1,001 (70.84)   231 (60.31)   770 (74.76)      1,091 (73.57)   364 (94.55)   727 (66.21)

  　Female              412 (29.16)     152 (39.69)   260 (25.24)      392 (26.43)     21 (5.45)     371 (33.79)

  Age                                                                                                

  　Non-elderly         607 (42.96)     234 (61.10)   373 (36.21)      423 (28.52)     165 (42.86)   258 (23.50)

  　Elderly             806 (57.04)     149 (38.90)   657 (63.79)      1,060 (71.48)   220 (57.14)   840 (76.50)

  Clinical stage\*                                                                                   

  　I                   326 (26.92)     99 (28.21)    227 (26.40)      324 (27.79)     97 (27.71)    227 (27.82)

  　II                  360 (29.73)     88 (25.07)    272 (31.63)      311 (26.67)     83 (23.71)    228 (27.94)

  　III                 371 (30.64)     106 (30.20)   265 (30.81)      327 (28.04)     107 (30.57)   220 (26.96)

  　IV                  154 (12.72)     58 (16.52)    96 (11.16)       204 (17.50)     63 (18.00)    141 (17.28)

  Pathologic type\*\*                                                                                

  　Adenocarcinoma      1,076 (77.80)   287 (74.93)   789 (78.90)      34 (2.37)       9 (2.34)      25 (2.38)

  　Squamous cell\      −               −             −                1,061 (73.89)   326 (84.68)   735 (69.93)
  　carcinoma                                                                                        

  　Other               307 (22.20)     96 (25.07)    211 (21.10)      341 (23.75)     50 (12.99)    291 (27.69)

  Treatment                                                                                          

  　Surgery             696 (49.26)     251 (65.54)   445 (43.20)      747 (50.37)     223 (57.92)   524 (47.72)

  　Radiotherapy        36 (2.55)       −             36 (3.50)        206 (13.89)     13 (3.38)     193 (17.58)

  　Chemotherapy        391 (27.67)     79 (20.63)    312 (30.29)      219 (14.77)     93 (24.16)    126 (11.48)

  　Concurrent\         21 (1.49)       10 (2.61)     11 (1.07)        119 (8.02)      23 (5.97)     96 (8.74)
  　chemoradiotherapy                                                                                

  　Palliative care     269 (19.04)     43 (11.23)    226 (21.94)      192 (12.95)     33 (8.57)     159 (14.48)
  ----------------------------------------------------------------------------------------------------------------

ACI of stomach and esophageal cancer patients {#s03.02}
---------------------------------------------

As shown in *[Table 2](#Table2){ref-type="table"}*, ACI of stomach and esophageal cancer patients in all seven study sites were \$5,694 and \$6,342, respectively. Non-elderly patients generally had greater ACI compared with the elderly ones for both cancers. ACI of adenocarcinoma was the greatest for both cancers. Furthermore, stage IV was associated with the lowest ACI for both cancers in all stages while surgery was associated with the highest in all the treatment modalities, followed by concurrent chemoradiotherapy, chemotherapy, palliative care and radiotherapy.

###### 

ACI of stomach and esophageal cancer patients by area (\$)

  -------------------------------------------------------------------------------------------------
  Variables             Stomach cancer             Esophageal cancer                        
  --------------------- ---------------- --------- ------------------- -- -------- -------- -------
  All                   5,694            10,449    2,927                  6,342    13,029   3,504

  Sex                                                                                       

  　Male                5,562            11,150    2,930                  7,253    13,317   3,636

  　Female              6,032            9,350     2,886                  3,748    8,279    3,261

  Age                                                                                       

  　Non-elderly         6,244            9,797     3,065                  8,049    13,869   3,289

  　Elderly             5,316            11,359    2,850                  5,584    12,422   3,572

  Clinical stage\*                                                                          

  　I                   9,365            23,172    2,954                  9,502    39,884   3,769

  　II                  6,358            22,544    3,352                  7,463    38,150   3,791

  　III                 7,525            16,262    3,262                  9,882    25,985   3,710

  　IV                  5,550            10,445    2,938                  5,069    9,128    3,640

  Pathologic type\*\*                                                                       

  　Adenocarcinoma      6,522            14,967    3,206                  14,064   18,542   7,969

  　Squamous cell\      −                −         −                      7,655    18,784   3,917
  　carcinoma                                                                               

  　Other               6,491            12,280    2,049                  3,238    9,690    2,020

  Treatment                                                                                 

  　Surgery             10,601           18,578    4,069                  12,179   44,195   3,431

  　Radiotherapy        2,444            −\*\*\*   2,264                  5,132    23,948   3,708

  　Chemotherapy        5,256            9,728     3,169                  5,869    7,839    3,741

  　Concurrent\         5,918            11,792    4,190                  10,064   30,412   5,301
  　chemoradiotherapy                                                                       

  　Palliative care     4,331            10,770    2,587                  5,262    9,255    3,566
  -------------------------------------------------------------------------------------------------

ACI in urban areas were \$10,449 for stomach cancer and \$13,029 for esophageal cancer while the values were \$2,927 and \$3,504 respectively in rural areas. For both cancers, ACI of men was greater than that of women in both areas. The financial burden associated with early stages (I and II) were substantially higher than that associated with advanced stages (III and IV) in urban areas, while no such difference was found in rural areas. Surgery was associated with the highest ACI in urban areas while it was preceded by concurrent chemoradiotherapy in rural areas for both cancers.

CPH of stomach and esophageal cancer patients {#s03.03}
---------------------------------------------

As shown in *[Table 3](#Table3){ref-type="table"}*, CPH of stomach and esophageal cancer patients in all seven study sites were \$2,294 and \$2,863 respectively. In urban areas, elderly patients were associated with greater CPH, while in rural areas, a negative association between age and CPH was found. Furthermore, differences of CPH among clinical stages and treatment modalities were statistically significant for both cancers (P\<0.0001), with stage I and surgery having the greatest CPH.

###### 

CPH of stomach and esophageal cancer patients by area

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables             Stomach cancer              Esophageal cancer                                                                                                    
  --------------------- ---------------- ---------- ------------------- ------- ---------- -- ------- ---------- -- ------- ---------- -- -------- ---------- -- ------- ----------
  All                   2,294            −                              2,938   −             1,224   −             2,863   −             3,994    −             1,768   −

  Sex                                                                                                                                                                    

  　Male                2,263            0.0001                         2,964   0.5690        1,235   0.4345        3,059   \<0.0001      4,014    0.3113        1,783   0.7015

  　Female              2,370                                           2,882                 1,183                 2,021                 3,658                  1,736   

  Age                                                                                                                                                                    

  　Non-elderly         2,238            0.5193                         2,698   \<0.0001      1,195   0.1607        3,229   \<0.0001      3,972    0.8039        1,605   0.0424

  　Elderly             2,360                                           3,310                 1,246                 2,638                 4,018                  1,818   

  Clinical stage\*                                                                                                                                                       

  　I                   4,255            \<0.0001                       7,459   \<0.0001      1,379   0.1385        4,328   \<0.0001      13,164   \<0.0001      1,879   0.2811

  　II                  2,371                                           7,098                 1,173                 3,180                 11,796                 1,767   

  　III                 2,739                                           4,258                 1,217                 4,142                 7,590                  1,760   

  　IV                  2,012                                           2,838                 1,119                 1,883                 2,603                  1,564   

  Pathologic type\*\*                                                                                                                                                    

  　Adenocarcinoma      2,451            \<0.0001                       3,983   \<0.0001      1,230   0.2437        4,502   \<0.0001      5,856    0.1243        2,390   0.0020

  　Squamous cell\      −                                               −                     −                     3,183                 5,686                  1,834   
  　carcinoma                                                                                                                                                            

  　Other               4,012                                           6,048                 1,293                 2,146                 4,283                  1,412   

  Treatment                                                                                                                                                              

  　Surgery             6,725            \<0.0001                       8,715   \<0.0001      3,062   \<0.0001      6,962   \<0.0001      16,053   \<0.0001      2,485   \<0.0001

  　Radiotherapy        1,187                                           4,551                 1,062                 2,671                 6,656                  1,875   

  　Chemotherapy        1,467                                           1,773                 858                   1,968                 2,260                  1,336   

  　Concurrent\         1,497                                           4,887                 1,277                 4,640                 8,925                  2,571   
  　chemoradiotherapy                                                                                                                                                    

  　Palliative care     1,205                                           1,449                 745                   1,511                 1,825                  983     
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CPH in urban areas were \$2,938 for stomach cancer and \$3,994 for esophageal cancer while the values were \$1,224 and \$1,768, respectively in rural areas. Unlike the patterns shown in all areas, no significant sexual difference of CPH was found while greater CPH was constantly associated with elderly patients for both cancers in urban and rural areas. Significant difference of CPH among clinical stages was found for both cancers only in urban areas and early stages were generally associated with greater CPH. Except for rural esophageal cancer patients, surgery had the highest CPH among all treatment modalities.

Proportional breakdown of CPH {#s03.04}
-----------------------------

As shown in *[Figure 2](#Figure2){ref-type="fig"}*, for stomach cancer, western medicine fee accounted for the largest proportion of CPH in both areas (urban: 42.7%, rural: 43.0%), followed by material fee (25.2%) and diagnosis fee (15.3%) in urban areas, diagnosis fee (22.9%) and non-surgical treatment fee (11.2%) in rural areas. For esophageal cancer, western medicine fee had the largest proportion in both areas as well (urban: 37.8%, rural: 34.3%), followed by material fee (19.8%) and non-surgical treatment fee (17.2%) in urban areas, non-surgical treatment fee (34.0%) and diagnosis fee (16.6%) in rural areas.

![Proportional breakdown of cost per hospitalization (CPH) by cancer and area.](cjcr-30-4-439-2){#Figure2}

Discussion {#s04}
==========

In this study, we examined the ACI of stomach and esophageal cancer patients in urban and rural areas in China using year-long data from seven cities/counties. We found that ACI of urban stomach and esophageal cancer patients were \$10,449 and \$13,029 while ACI of rural patients were \$2,927 and \$3,504, respectively. By contrast, in 2016, annual income of urban and rural residents in China were \$5,061 and \$1,861, respectively ([@b21]). Male and non-elderly patients were associated with heavier burden while other indicators of heavy burden were early stages and surgery as the primary treatment modality. Annual direct medical costs, direct non-medical costs and indirect costs were shown in *[Supplementary Table S2](#TableS2){ref-type="table"}*, *[S3](#TableS3){ref-type="table"}* and *[S4](#TableS4){ref-type="table"}*.

###### 

Annual direct medical cost of sampled former stomach and esophageal cancer patients by area (\$)

  Variables                        Stomach cancer            Esophageal cancer                        
  -------------------------------- ---------------- -------- ------------------- -- -------- -------- -------
  All                              4,473            8,550    1,958                  5,325    11,543   2,652
  Sex                                                                                                 
  　Male                           4,390            9,337    1,951                  6,179    11,841   2,764
  　Female                         4,693            7,320    1,952                  2,890    6,621    2,448
  Age                                                                                                 
  　Non-elderly                    4,946            8,040    2,055                  6,975    12,393   2,472
  　Elderly                        4,154            9,235    1,906                  4,590    10,929   2,709
  Clinical stage\*                                                                                    
  　I                              8,255            21,482   2,096                  8,483    38,439   2,931
  　II                             5,169            21,081   2,252                  6,710    37,393   3,039
  　III                            5,944            13,498   2,154                  8,408    23,681   2,640
  　IV                             3,863            8,457    1,432                  3,747    7,393    2,502
  Pathologic type\*\*                                                                                 
  　Adenocarcinoma                 5,270            13,303   2,103                  12,696   16,924   6,692
  　Squamous cell carcinoma        −                −        −                      6,526    17,286   2,953
  　Other                          5,336            9,677    1,552                  2,661    8,309    1,581
  Treatment                                                                                           
  　Surgery                        9,617            16,820   3,521                  11,418   42,701   2,982
  　Radiotherapy                   1,709            −        1,529                  4,007    23,030   2,569
  　Chemotherapy                   3,697            7,411    1,802                  4,526    6,125    2,672
  　Concurrent chemoradiotherapy   2,350            6,353    2,324                  8,770    29,096   4,011
  　Palliative care                3,109            9,636    1,348                  3,913    8,121    2,172

###### 

Annual direct non-medical cost of sampled former stomach and esophageal cancer patients by area (\$)

  Variables                        Stomach cancer         Esophageal cancer                  
  -------------------------------- ---------------- ----- ------------------- -- ----- ----- -----
  All                              342              501   283                    279   384   242
  Sex                                                                                        
  　Male                           338              449   304                    298   376   259
  　Female                         352              579   218                    225   529   208
  Age                                                                                        
  　Non-elderly                    356              454   294                    294   345   261
  　Elderly                        331              575   276                    273   413   236
  Clinical stage\*                                                                           
  　I                              315              411   274                    330   371   313
  　II                             345              477   302                    270   221   288
  　III                            445              709   339                    308   494   218
  　IV                             385              420   364                    269   467   181
  Pathologic type\*\*                                                                        
  　Adenocarcinoma                 315              349   303                    282   8     380
  　Squamous cell carcinoma        −                −     −                      281   362   244
  　Other                          443              955   210                    210   595   144
  Treatment                                                                                  
  　Surgery                        320              541   195                    217   358   157
  　Radiotherapy                   140              −     140                    211   417   197
  　Chemotherapy                   370              411   359                    389   459   337
  　Concurrent chemoradiotherapy   574              863   311                    280   315   272
  　Palliative care                367              349   371                    464   388   480

###### 

Annual indirect cost of sampled former stomach and esophageal cancer patients by area (\$)

  Variable                         Stomach cancer           Esophageal cancer                      
  -------------------------------- ---------------- ------- ------------------- -- ------- ------- -------
  All                              879              1,398   686                    738     1,102   610
  Sex                                                                                              
  　Male                           834              1,364   675                    776     1,100   613
  　Female                         987              1,451   716                    633     1,129   605
  Age                                                                                              
  　Non-elderly                    942              1,303   716                    780     1,131   556
  　Elderly                        831              1,549   668                    721     1,080   627
  Clinical stage\*                                                                                 
  　I                              795              1,279   584                    689     1,074   525
  　II                             844              986     798                    483     536     464
  　III                            1,136            2,055   769                    1,166   1,810   852
  　IV                             1,302            1,568   1,142                  1,053   1,268   957
  Pathologic type\*\*                                                                              
  　Adenocarcinoma                 937              1,315   800                    1,086   1,610   897
  　Squamous cell carcinoma        −                −       −                      848     1,136   720
  　Other                          712              1,648   287                    367     786     295
  Treatment                                                                                        
  　Surgery                        664              1217    353                    544     1,136   292
  　Radiotherapy                   595              −       595                    914     501     942
  　Chemotherapy                   1,189            1,906   1,008                  954     1,255   732
  　Concurrent chemoradiotherapy   2,994            4,576   1,555                  1,014   1,001   1,018
  　Palliative care                855              785     868                    885     746     914

In our study, the financial burden of esophageal cancer was heavier compared with stomach cancer, as proved by previous studies in Ontario ([@b9]) and Hua county, a high-risk area of upper gastrointestinal cancer ([@b5]), whereas in Anhui province, a typical inland province in China, stomach cancer was the costliest cancer ([@b6]), The proportion of men was substantially higher than that of women in our analysis, as was found of the incidence rate in population-based cancer registration ([@b3],[@b20]).

Urban costs were constantly higher than rural costs in our study, partly because urban data were extracted from two Grade 3 hospitals, which are both provincial hospitals, while rural data were mainly from Grade 2 and county level hospitals. Hospitals in China were categorized into three grades based on their function and facilities, with Grade 3 as the highest. Previous studies pointed out that medical cost increased monotonically with hospital level and grade ([@b5],[@b22]). The gap of costs indicated that the lopsided distribution of health resources between urban and rural China still existed ([@b23]) since hospitals with high levels are more likely to be located in cities rather than counties.

Previous studies in China tended to categorize age into four or more groups and found no clear association between medical expenditure and age group ([@b4],[@b6]). In this study, we categorized age into two groups and found that for both cancers, non-elderly patients were associated with lower CPH and more frequent hospitalization (*[Supplementary Table S5](#TableS5){ref-type="table"}*) in urban and rural areas whereas in Japan, greater medical costs were associated with elderly patients ([@b11]). As a result, heavier ACI was found for non-elderly patients in all areas combined, as was found in a study on colorectal, breast and prostate cancer patients in US ([@b24]). Though evidences showed that age did not affect overall surgical outcomes ([@b25],[@b26]), surgery was still applied less frequently to elderly patients ([@b27]). Overall mean cost of surgical group was higher than that of non-surgical group, according to an Australian study ([@b8]), further proved our results. One main reason for the high cost of surgery was the postoperative complication ([@b28],[@b29]). Additional costs of severe complications could account for 27% of the total hospitalization costs ([@b28]). Hospitalization costs reduction could be achieved by not only reducing complications after surgery but also increasing the number of experienced surgeons ([@b29],[@b30]). Moreover, high costs notwithstanding, surgical resection has the greatest benefit in terms of survival and is proved to be at least as cost-effective as other treatment modalities ([@b31]).

###### 

Annual number of hospitalization of sampled former stomach and esophageal cancer patients by area (d)

  Variable                         Stomach cancer          Esophageal cancer                    
  -------------------------------- ---------------- ------ ------------------- -- ------ ------ ------
  All                              1.95             2.91   1.60                   1.86   2.89   1.50
  Sex                                                                                           
  　Male                           1.94             3.15   1.58                   2.02   2.95   1.55
  　Female                         1.98             2.54   1.65                   1.43   1.81   1.41
  Age                                                                                           
  　Non-elderly                    2.21             2.98   1.72                   2.16   3.12   1.54
  　Elderly                        1.76             2.79   1.53                   1.74   2.72   1.49
  Clinical stage\*                                                                              
  　I                              1.94             2.88   1.52                   1.96   2.92   1.56
  　II                             2.18             2.97   1.92                   2.11   3.17   1.72
  　III                            2.17             3.17   1.77                   2.03   3.12   1.50
  　IV                             1.92             2.98   1.28                   1.99   2.84   1.60
  Pathologic type\*\*                                                                           
  　Adenocarcinoma                 2.15             3.34   1.71                   2.82   2.89   2.80
  　Squamous cell carcinoma        −                −      −                      2.05   3.04   1.61
  　Other                          1.33             1.60   1.20                   1.24   1.94   1.12
  Treatment                                                                                     
  　Surgery                        1.43             1.93   1.15                   1.64   2.66   1.20
  　Radiotherapy                   1.44             −      1.44                   1.50   3.46   1.37
  　Chemotherapy                   2.52             4.18   2.10                   2.30   2.71   2.00
  　Concurrent chemoradiotherapy   1.57             1.30   1.82                   1.89   3.26   1.56
  　Palliative care                2.58             6.65   1.81                   2.59   4.45   2.21

ACI generally decreased as the clinical stage increased for both cancers, especially in urban areas. Guo *et al.* ([@b4]) reported that for esophageal cancer, stage II patients had the highest medical expenditure during 2009−2011 in urban China. In terms of hospitalization cost per patient that covered the first year after diagnosis, stage II was the most expensive for esophageal cancer patients in Northern Ireland as well ([@b7]) whereas in Korea, advanced stages at diagnosis were associated with 1.8−2.5 folds higher costs ([@b10]). Compared with patients in US, Chinese stomach cancer patients had larger tumors and later stages ([@b32]), which were generally associated with shorter survival ([@b33]). The majority of patients included in this study were also at stage III or IV. Therefore, even though screening could detect cancer at early stage and was proved cost-effective or cost-benefit by Chinese and international studies ([@b34]-[@b36]), the possibility that the annual expenditures on treatment may increase along with survival remains to the beneficiaries of screening programs.

Urban employee basic medical insurance (UEBMI), urban resident basic medical insurance (URBMI) and new rural cooperative medical scheme (NCMS) are the three mainstream health insurance schemes in China. By 2010, the percentage of the Chinese population covered by these three schemes rose from 23% in 2003 to over 90% ([@b37]). Notwithstanding, the financial protections offered are very modest and out-of-pocket spending was hardly reduced ([@b37],[@b38]). The findings in this study quantified the ACI of stomach and esophageal cancer of Chinese patients in both urban and rural areas, suggesting that preferential medical insurance policies should be designed at least in the high-risk areas of upper gastrointestinal cancer to further reduce the health inequalities ([@b38]).

Our research had the following strengths. The seven chosen hospitals are responsible for the treatment of the majority of the local residents in the seven study sites which cover both urban and rural areas and three economical-geographical regions in China ([@b18]). Data of all cases discharged in the whole year were extracted without omission and the results of urban and rural areas were reported separately.

The results of our study should be seen in the light of its limitations as well. The five types of therapy in this research are all broad concepts containing various methods whereas the LOS and cost of each method varied ([@b39]-[@b43]). In this research, all methods of each type of therapy were classified simply into one modality. Consequently, the inherent difference between each method could not be analyzed. Therefore, further investigations with more elaborate designs were needed.

Conclusions {#s05}
===========

Stomach cancer and esophageal cancer are imposing tremendous burdens on Chinese people both epidemiologically and financially. We observed a huge gap of the ACI of stomach and esophageal cancer between urban and rural areas, indicating the lopsided distribution of health resources in China and the burden of esophageal cancer was constantly heavier than stomach cancer. Furthermore, the burden varied substantially with clinical stage, treatment modality, pathologic type and other clinical characteristics. Preferential policies of medical insurance should be designed to tackle with this burden, especially in the high-risk areas of stomach or esophageal cancer.
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